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Background: Acquired abnormalities of coagulation and fibrinolysis in nephrotic syndrome have been Renal Vein Thrombosis ( RVT ) is a well recognised implicated in the pathogenesis of renal vein thrombosis thrombotic complication of nephrotic syndrome. Its ( RVT ). Whether resistance to activated Protein C prevalence is uncertain but has been reported to vary due to a mutation in the gene for factor V (FV from 5% when only clinical criteria are used for further Leiden/FV506Q, the commonest inherited risk factor evaluation, to as high as 50% if evidence for thromfor venous thrombosis) could contribute to risk of bus is actively sought in asymptomatic patients RVT in patients with nephrotic syndrome is unknown. [1] . Intravascular volume depletion, immobilisation, Methods: Genotyping for the factor V Leiden mutation abnormalities of pro-coagulant and anticoagulant was undertaken in a retrospective study of 35 patients mechanisms including elevated fibrinogen and its with a history of nephrotic syndrome, 10 of whom had deposition as fibrin, increased urinary loss of antisuÂered clinically significant and radiologically coagulant factors such as antithrombin III and free proven RVT.
Protein S may all contribute to risk of RVT [2] [3] [4] [5] . Results: Two patients (6%) were heterozygous for the Evidence for a procoagulant state is also shown by FV506Q mutation, a prevalence similar to studies raised indices of the coagulation activation peptide within the general population. One heterozygote had Prothrombin fragment F1+2 and thrombinsuÂered a RVT, whilst the other without a native RVT antithrombin complexes [6 ] . In adults, membranous subsequently had a primary renal allograft thrombosis. nephropathy appears to be particularly associated with Conclusions: In a retrospective study the prevalence of risk of renal vein thrombosis [2, 5] . Proteins C and S the FV Leiden mutation was not increased in patients provide a major endothelial anticoagulant defence with nephrotic syndrome nor associated with preval-mechanism and inherited deficiencies due to genetic ence of clinically significant RVT. Whilst this study defects are associated with increased risk of venous was insuÃciently powerful to fully exclude an associ-thrombosis in the general population [7 ] . These mutaation, it suggests acquired rather than inherited altera-tions however are heterogeneous and uncommon, tions in the coagulation/fibrinolytic balance associated occurring in only 0.1-0.5% of the population. with nephrosis may be of greater importance in venous Activated protein C ( APC ) resistance has recently thrombotic risk, and that routine screening of patients been found to be strongly associated with inherited with nephrosis for this mutation will not identify the risk of venous thrombosis [8 ] . A major contributor to majority of patients at risk for RVT. Confirmation of the impairment of the anti-coagulant eÂect of activated these results and determining whether the natural Protein C is due to a G/A substitution at base pair history of thrombosis or underlying renal disease in 1691 in factor V (FV ) resulting in the substitution of carriers of the FV Leiden mutation diÂers from those glutamine (Q ) for arginine (R) at amino acid 506 [9 ] . without this mutation, will require a large prospective FV506Q ( FV Leiden) retards the degradation of activstudy.
ated factor V (Va) by activated protein C~10 fold compared with FV506R, and promotes continuing Key words: Nephrotic syndrome; renal vein thrombosis; thrombin generation leading to a hypercoagulable state factor V Leiden mutation [10] . APC resistance due to FV506Q has been shown to be associated with increased risk of venous thrombosis in the general population [8] , oral contraceptive users [11 ] , and the risk of primary venous thrombosis in healthy men [12] . These studies suggest that~5% The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome 1681 were then subjected to 95°C×5 min, 55°C×1 min, 72°C×1 inherited risk factor for venous thrombosis identified. min then 30 cycles of 95°C x 1 min, 55°C×1 min and 72°C
One case report documents venous thrombosis in a ×1 min. Ten ml of the PCR product were digested with 1 U carrier of this mutation with membranous nephropathy of the restriction enzyme Mnl1 (New England Biolabs) for and nephrotic syndrome [13] . The present study was 12 h at 37°C and the digestion products were separated by performed to assess if the risk of renal venous throm-electrophoresis through a 2% agarose gel containing ethidium bosis in the setting of nephrotic syndrome was associ-bromide and visualised under UV light. Internal controls of ated with the FV506Q mutation. a homozygote for FV506Q and a heterozygote, previously genotyped using diÂerent PCR primers, were included on each run. All patients positive for the FV mutation were
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confirmed by repeating the PCR and digestion at least twice.
Ten adult patients with a diagnosis of renal vein thrombosis Statistics and nephrotic syndrome were identified from the records of the Oxford Renal Unit, which services a population of~2 Categorical data were compared by Chi-square or Fisher's million, over the last 15 years. 25 other patients who had a exact test, means by unpaired t-test and medians by Mann diagnosis of nephrotic syndrome without a history of renal Whitney U-test using Instat Computer Software. Assuming venous thrombosis during this period were used as controls. that the inheritance of one FV506Q allele in the general It was not possible to precisely match the severity or duration population is reported to give an odds ratio (OR) for venous of nephrotic syndrome between the two groups but histo-thrombotic risk of between 5-10, at a a of 0.05 and b of 0.1, logical diagnosis, disease progression and sex matching were we would require 57 (OR=5) or 19 (OR=10) patients in closely approximated. No patient had a familial history of each group respectively to have a 90% probability of avoiding venous thrombosis. All patients had undergone renal biopsy a type II error. for histological diagnosis except two patients with extensive thrombosis requiring anticoagulation where biopsy was considered too hazardous. Nephrotic syndrome was defined as Results plasma albumin <30g/l and urinary protein excretion >3.5g/day. Oedema was usually but not always present. The period of nephrotic syndrome varied from 3 months to >10 Demographic details of the two groups are recorded years. Renal Vein thrombosis was definitively diagnosed by in Table 1 . The two patient groups did not diÂer any or several of the following techniques; renal vein venogra-according to age, sex, diagnosis, or progression to end phy, MRI or contrast enhanced CT scanning. Eight patients stage renal failure. Two patients were heterozygous for with RVT were diagnosed at presentation with nephrotic the FV506Q mutation (prevalence 6%), both of whom syndrome, one patient had RVT diagnosed in the context of had membranous nephropathy. The distribution of FV a sudden deterioration in renal function 12 months after Leiden genotype and RVT is shown in Table 2 . There initial presentation, and another patient had the diagnosis was no significant diÂerence in the distribution of the delayed until 4 months following presentation. Nine had FV506Q mutation according to presence or absence of evidence of pulmonary embolism and all were anti-coagulated either for life, or for the duration of their nephrotic syndrome. Prophylactic anti-coagulation was not used and in the patients had subsequent diagnoses of malignancy (adenocar- This study was approved by the regional ethics committee. An additional 321 patients attending the same renal unit(61% 1FSGS=Focal and segmental hyalinosis and sclerosis. male, median age 50) with chronic renal disease (33% with 2ESRF=End-stage renal failure. a histological diagnosis of glomerulonephritis) were studied by identical techniques and provided a control population Table 2 . Prevalence of factor V Leiden mutation (FV506Q ) and for comparison of prevalence of the FV506Q mutation.
presence (+) or absence (-) of renal vein thrombosis ( RVT) in 35
Patients were genotyped by a slight modification of the patients with nephrotic syndrome method originally described by Bertina et al. [9 ] . DNA was prepared from whole blood by a rapid method RVT+ 
RVT− Total
[ 14] and PCR amplified using the primers described by Bertina et al.
[9] for the 267bp fragment of factor V: ( 5∞ to 3∞) TGCCCAGTGCTTAACAAGACCA and TGTTAT-FV506Q a RVT. The additional patient heterozygous for the loss of patients with the FV506Q may underestimate this risk, however no study in the general population FV506Q mutation without evidence of a RVT underwent pre-end stage renal transplantation and suÂered has identified this mutation as associated with increased risk of death, indeed the high prevalence of this mutaa primary renal transplant vein thrombosis. Hence both FV506Q heterozygous patients had a venous tion suggests otherwise [17 ] . It is possible a true association was not detected because the power of this thrombosis compared to 9/33 of those negative (P= 0.09 Fishers exact test). Both FV506Q heterozygotes study was insuÃcient, or because subclinical thrombosis, (which was not actively sought) was not detected progressed to end-stage renal failure (ESRF ) compared with 12 of the remaining 33 patients (P=0.15). and patients were misclassified. Only a larger ( probably multicentre) study can address the issue of power, but In the additional 321 patients with chronic renal disease, 16 (5%) were heterozygous for the FV506Q allele, misclassification appears unlikely to influence the results because the prevalence of the FV506Q allele not statistically diÂerent from the 35 patients with nephrotic syndrome (P=0.7). The genotypes were in was not increased in either patient group when compared with a large chronic renal disease control group Hardy-Weinberg equilibrium.
nor reported prevalence studies. Whilst precise matching of severity and duration of nephrosis was impossDiscussion ible, a similar proportion developed end-stage renal failure suggesting severity of disease was approximated, and nine of the patients had evidence of RVT at This retrospective study shows that the prevalence of the FV Leiden mutation in a selected group of patients presentation, suggesting risk of clinical events was maximal early in the disease course. with nephrotic syndrome was 6%, consistent with the prevalence reported in other studies drawn from Screening for additional coagulation abnormalities, and correlation with functional evaluation for APC European and North American populations, and with a further large cohort of patients with chronic renal resistance was not undertaken in this study due to the uncertainty regarding potential confounding by the disease attending the same renal unit. The prevalence did not diÂer significantly between the patients with heterogeneity of current clinical status including continuous anticoagulation, resolution or progression of or without renal vein thrombosis. The FV Leiden mutation is the most common genetic risk for venous disease status, or great temporal dislocation from the clinical event which would not allow meaningful retrothrombosis and in selected populations with deep venous thrombosis or pulmonary embolism, hetero-spective comparison between patients. Co-inheritance of associated mutations in the genes for protein C or zygosity for this mutation confers an increased risk of venous thrombosis of between 5-10 fold, and homo-S for example has been shown to significantly increase the risk of clinical events in familial thrombosis in zygosity 50-100 fold [10 ]. In healthy men followed in a prospective study the FV Leiden mutation conferred patients with APC resistance [10 ], but as none of the patients in this study had a familial history of venous an increased risk of primary but not secondary venous thrombosis and predicted increased risk of recurrent thrombosis, the presence of additional mutations would be unlikely. In this study, genotyping for the thrombosis [15 ] . The majority of patients heterozygous for this mutation may however, suÂer no adverse event factor V506Q mutation had the advantage of independence from transient and changing environmental facunless an environmental precipitant is encountered such as surgery, pregnancy or the oral contraceptive tors measured at varying intervals from the clinical event and indicated a life-long estimate of venous [16 ] . The present study does not suggest that the FV Leiden mutation was significantly associated with the thrombotic risk.
Whether patients with venous thrombosis, or popuprevalence of renal vein thrombosis associated with nephrotic syndrome. Although one case report has lations at risk, should be screened for the FV Leiden mutation is being vigorously debated [18, 19] . Evidence identified the occurrence of lower limb venous thrombosis in a carrier of the mutation who presented with is accumulating that this mutation contributes significantly to venous thrombotic risk in the general popunephrotic syndrome [13] , the relatively high prevalence of the FV Leiden mutation in the general population lation. Information derived from screening gives a lifelong index of thrombotic risk, may assist in decision suggests that this association will be likely to occur by chance alone. The finding that both patients who making regarding length of anti-coagulation and risk of recurrence, and can be undertaken whilst the patient carried the FV Leiden mutation suÂered a venous thrombosis (native or renal allograft vein thrombosis), is anti-coagulated. Additional studies examining the FV506Q mutation in diÂering disease states associated is consistent with evidence suggesting heterozygosity for the FV Leiden mutation is a risk factor for venous with thrombosis, and in case reports [20 ] , will continue to generate information regarding its pathological conthrombosis, but the lack of an association with the majority of thrombotic events in this study argues that sequences, indications for screening and therapeutic interventions under diÂerent circumstances. Whilst this the acquired abnormalities of coagulation and fibrinolysis associated with nephrotic syndrome are of study does not suggest a significant role for the FV506Q mutation and risk of RVT in nephrotic syngreater relevance. However, several limitations of this study require caution in interpretation of these results. drome, screening patients may still be worthwhile because it is relatively simple, inexpensive and may It is possible that in a retrospective study, selective
